TY - JOUR
T1 - Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma
AU - Albiges, Laurence
AU - Salem, Mohamed
AU - Rini, Brian
AU - Escudier, Bernard
PY - 2011/8/1
Y1 - 2011/8/1
N2 - Vascular endothelial growth factor (VEGF) is, to date, the key element in the pathogenesis of renal cell carcinoma (RCC). VEGF pathway activation is responsible for the recruitment, migration, and expansion of endothelial cells, with this angiogenesis tumor model being characteristic of RCC. Different strategies have been developed for almost a decade to block the VEGF pathway in this setting. Four different compounds were approved for metastatic RCC (mRCC) in the past 6 years: bevacizumab, sunitinib, sorafenib, and pazopanib. Axitinib and tivozanib are also promising compounds under evaluation. The revolution in the management and prognosis of patients with mRCC is ongoing.
AB - Vascular endothelial growth factor (VEGF) is, to date, the key element in the pathogenesis of renal cell carcinoma (RCC). VEGF pathway activation is responsible for the recruitment, migration, and expansion of endothelial cells, with this angiogenesis tumor model being characteristic of RCC. Different strategies have been developed for almost a decade to block the VEGF pathway in this setting. Four different compounds were approved for metastatic RCC (mRCC) in the past 6 years: bevacizumab, sunitinib, sorafenib, and pazopanib. Axitinib and tivozanib are also promising compounds under evaluation. The revolution in the management and prognosis of patients with mRCC is ongoing.
KW - Bevacizumab
KW - Clear cell carcinoma
KW - HIF
KW - Pazopanib
KW - Renal cell carcinoma
KW - Sorafenib
KW - Sunitinib
KW - Vascular endothelial growth factor
UR - http://www.scopus.com/inward/record.url?scp=79960365945&partnerID=8YFLogxK
U2 - 10.1016/j.hoc.2011.04.006
DO - 10.1016/j.hoc.2011.04.006
M3 - Review article
C2 - 21763969
AN - SCOPUS:79960365945
SN - 0889-8588
VL - 25
SP - 813
EP - 833
JO - Hematology/Oncology Clinics of North America
JF - Hematology/Oncology Clinics of North America
IS - 4
ER -